Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Diabetic Neuropathic Pain Overview 9 Therapeutics Development 10 Pipeline Products for Diabetic Neuropathic Pain - Overview 10 Pipeline Products for Diabetic Neuropathic Pain - Comparative Analysis 11 Diabetic Neuropathic Pain - Therapeutics under Development by Companies 12 Diabetic Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes 14 Diabetic Neuropathic Pain - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Diabetic Neuropathic Pain - Products under Development by Companies 18 Diabetic Neuropathic Pain - Products under Investigation by Universities/Institutes 19 Diabetic Neuropathic Pain - Companies Involved in Therapeutics Development 20 Astellas Pharma Inc. 20 BioDelivery Sciences International, Inc. 21 Boehringer Ingelheim GmbH 22 Daiichi Sankyo Company, Limited 23 Eli Lilly and Company 24 Glenmark Pharmaceuticals Ltd. 25 Hydra Biosciences, Inc. 26 Immune Pharmaceuticals Inc. 27 Laboratorios Del Dr. Esteve S.A. 28 Lohocla Research Corporation 29 Mertiva AB 30 Novaremed 31 PeriphaGen, Inc. 32 Pharmaleads 33 Prismic Pharmaceuticals, Inc. 34 Relmada Therapeutics, Inc. 35 Sphaera Pharma Pvt. Ltd. 36 Theravasc, Inc. 37 Diabetic Neuropathic Pain - Therapeutics Assessment 38 Assessment by Monotherapy Products 38 Assessment by Combination Products 39 Assessment by Target 40 Assessment by Mechanism of Action 42 Assessment by Route of Administration 44 Assessment by Molecule Type 46 Drug Profiles 48 (amitriptyline + ketamine hydrochloride) - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 (diclofenac sodium + triclocarban) - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 AS-1069562 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 ASP-3662 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 capsaicin - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 clonidine hydrochloride - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 duloxetine hydrochloride DR - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 E-52862 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 EC-5026 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 filgrastim - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 GERPOOI - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 GRC-17536 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 HC-030031 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Kindolor - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 mepivacaine hydrochloride - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 mirogabalin besylate - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 NG2-GAD - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 NRD-135SE1 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 palmidrol - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 PGN-305 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 PL-37 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 Small Molecule to Agonize CB2 for Diabetic Neuropathic Pain - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 sodium nitrite SR - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 Diabetic Neuropathic Pain - Recent Pipeline Updates 80 Diabetic Neuropathic Pain - Dormant Projects 88 Diabetic Neuropathic Pain - Discontinued Products 91 Diabetic Neuropathic Pain - Product Development Milestones 92 Featured News & Press Releases 92 Jan 06, 2016: Hydra Biosciences to Present at the 8th Annual Biotech Showcase Conference in San Francisco on Jan. 11 92 Sep 28, 2015: Pharmaleads Announces the Opening of French Sites in Its International Phase IIa Clinical Study of PL37 92 Apr 22, 2015: Pharmaleads Announces the Inclusion of the First Patient in Phase IIa Study of Oral PL37 for Pain in Diabetic Neuropathy 93 Mar 30, 2015: BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 94 Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin 94 Dec 08, 2014: BioDelivery Sciences Announces Completion of Randomization in Phase 3 Trial of Clonidine Topical Gel for the Treatment of Painful Diabetic Neuropathy 95 Aug 06, 2014: BioDelivery Sciences Provides Update on Ongoing Phase 3 Pivotal Trial for Clonidine Topical Gel for Painful Diabetic Neuropathy 96 Oct 30, 2012: Drug Offers New Pain Management Therapy For Diabetics, Study Finds 96 Jun 04, 2012: EpiCept Receives Scientific Advice From EMA For AmiKet CIPN Program 97 Feb 22, 2012: Shionogi And Lilly Japan Announce Approval Of Additional Indication For Cymbalta In Japan 97 Appendix 99 Methodology 99 Coverage 99 Secondary Research 99 Primary Research 99 Expert Panel Validation 99 Contact Us 99 Disclaimer 100

List of Tables Number of Products under Development for Diabetic Neuropathic Pain, H1 2016 10 Number of Products under Development for Diabetic Neuropathic Pain - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Development, H1 2016 17 Products under Development by Companies, H1 2016 18 Products under Investigation by Universities/Institutes, H1 2016 19 Diabetic Neuropathic Pain - Pipeline by Astellas Pharma Inc., H1 2016 20 Diabetic Neuropathic Pain - Pipeline by BioDelivery Sciences International, Inc., H1 2016 21 Diabetic Neuropathic Pain - Pipeline by Boehringer Ingelheim GmbH, H1 2016 22 Diabetic Neuropathic Pain - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 23 Diabetic Neuropathic Pain - Pipeline by Eli Lilly and Company, H1 2016 24 Diabetic Neuropathic Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2016 25 Diabetic Neuropathic Pain - Pipeline by Hydra Biosciences, Inc., H1 2016 26 Diabetic Neuropathic Pain - Pipeline by Immune Pharmaceuticals Inc., H1 2016 27 Diabetic Neuropathic Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2016 28 Diabetic Neuropathic Pain - Pipeline by Lohocla Research Corporation, H1 2016 29 Diabetic Neuropathic Pain - Pipeline by Mertiva AB, H1 2016 30 Diabetic Neuropathic Pain - Pipeline by Novaremed, H1 2016 31 Diabetic Neuropathic Pain - Pipeline by PeriphaGen, Inc., H1 2016 32 Diabetic Neuropathic Pain - Pipeline by Pharmaleads , H1 2016 33 Diabetic Neuropathic Pain - Pipeline by Prismic Pharmaceuticals, Inc., H1 2016 34 Diabetic Neuropathic Pain - Pipeline by Relmada Therapeutics, Inc., H1 2016 35 Diabetic Neuropathic Pain - Pipeline by Sphaera Pharma Pvt. Ltd., H1 2016 36 Diabetic Neuropathic Pain - Pipeline by Theravasc, Inc., H1 2016 37 Assessment by Monotherapy Products, H1 2016 38 Assessment by Combination Products, H1 2016 39 Number of Products by Stage and Target, H1 2016 41 Number of Products by Stage and Mechanism of Action, H1 2016 43 Number of Products by Stage and Route of Administration, H1 2016 45 Number of Products by Stage and Molecule Type, H1 2016 47 Diabetic Neuropathic Pain Therapeutics - Recent Pipeline Updates, H1 2016 80 Diabetic Neuropathic Pain - Dormant Projects, H1 2016 88 Diabetic Neuropathic Pain - Dormant Projects (Contd..1), H1 2016 89 Diabetic Neuropathic Pain - Dormant Projects (Contd..2), H1 2016 90 Diabetic Neuropathic Pain - Discontinued Products, H1 2016 91 List of Figures Number of Products under Development for Diabetic Neuropathic Pain, H1 2016 10 Number of Products under Development for Diabetic Neuropathic Pain - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Products, H1 2016 17 Assessment by Monotherapy Products, H1 2016 38 Assessment by Combination Products, H1 2016 39 Number of Products by Top 10 Targets, H1 2016 40 Number of Products by Stage and Top 10 Targets, H1 2016 40 Number of Products by Top 10 Mechanism of Actions, H1 2016 42 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 42 Number of Products by Routes of Administration, H1 2016 44 Number of Products by Stage and Routes of Administration, H1 2016 44 Number of Products by Molecule Types, H1 2016 46 Number of Products by Stage and Molecule Types, H1 2016 46

Astellas Pharma Inc. BioDelivery Sciences International, Inc. Boehringer Ingelheim GmbH Daiichi Sankyo Company, Limited Eli Lilly and Company Glenmark Pharmaceuticals Ltd. Hydra Biosciences, Inc. Immune Pharmaceuticals Inc. Laboratorios Del Dr. Esteve S.A. Lohocla Research Corporation Mertiva AB Novaremed PeriphaGen, Inc. Pharmaleads Prismic Pharmaceuticals, Inc. Relmada Therapeutics, Inc. Sphaera Pharma Pvt. Ltd. Theravasc, Inc.